NCT07271030

The Use of Cannabidiol Suppositories for Sexual Pain

The Use of Cannabidiol Suppositories for Sexual Pain: A Randomised Controlled Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: London Metropolitan University · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy. Outcomes are also hoped to increase sexual functioning, well-being, and quality of life. Research intention: If cannabidiol suppository intervention reduces sexual pain and increases general well-being, then this research would be repeated on a larger scale, targeting psychosexual services. A brief overview of the intervention: Quantitatively, randomisation of cannabidiol suppositories will be into dose-specific groups. The intervention will be delivered over a period of one month, with follow-up scheduled at 12 weeks. Qualitatively, participants were asked approximately eight open-ended feedback questions throughout the study.

Detailed description

Sexual pain is a constellation of biopsychosocial disorders which affects men, women and their partners. Cannabidiol is one of approximately 100 cannabinoids found in cannabis, alongside tetrahydrocannabinol. Cannabidiol is non-intoxicating and regarded as a safe product to use. Cannabidiol has many applications, including in sexual health. Two studies have examined cannabidiol suppositories for supporting sexual function and reducing sexual pain. In both studies, outcomes suggested the pain relieving qualities of cannabidiol oil for both men and women. This research aims to establish the effectiveness of varied doses of cannabidiol oil to minimise sexual pain and increase well-being. This research is a preliminary study looking at how cannabidiol suppositories aim to reduce pain and support sexual function, wellbeing and quality of life among those experiencing sexual discomfort or pain during intercourse or masturbation. There will be four groups, where cannabidiol will be randomised to dose-specific groups, approximately 30, 50, and 100mg, under the guidance of a medical practitioner. There will also be a care as usual group. It is hypothesised that: Higher levels of sexual functioning, quality of life and wellbeing with lower levels of sexual pain will be reported among those using cannabidiol suppositories at the follow-up after intervention compared to care as usual group. It is further hypothesised that higher doses of cannabidiol suppositories will have higher levels of sexual pain-reducing outcomes.

Conditions

• Well-Being, Psychological
• Quality of Life
• Sexual Behavior
• Sexual Pain Disorder

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Cannabidiol suppository intervention 1	Cannabidiol suppository dose specific 30mg
DIETARY_SUPPLEMENT	Cannabidiol suppository intervention 2	Cannabidiol suppository dose specific 50mg
DIETARY_SUPPLEMENT	Cannabidiol suppository intervention 3	Cannabidiol suppository dose specific 100mg
OTHER	Non cannabidiol group control	Care as usual group

Timeline

• Start date: 2026-01-16
• Primary completion: 2026-07-01
• Completion: 2026-08-01
• First posted: 2025-12-08
• Last updated: 2026-01-26

Locations

1 site across 1 country: United Kingdom